Creatinolfosfate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Creatinolfosfate API 6903-79-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Creatinolfosfate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Creatinolfosfate
- Synonyms:
- COP , Creatinolfosfate
- Cas Number:
- 6903-79-3
- DrugBank number:
- DB13071
- Unique Ingredient Identifier:
- 5O564RN1QD
General Description:
Creatinolfosfate, identified by CAS number 6903-79-3, is a notable compound with significant therapeutic applications. COP is under investigation for the treatment of Rheumatoid Arthritis, Mature B-Cell Lymphoma, and Noninflammatory Degenerative Joint Disease. COP has been investigated for the treatment of Diabetic Retinopathy.
Classification:
Creatinolfosfate belongs to the class of organic compounds known as phosphoethanolamines. These are compounds containing a phosphate linked to the second carbon of an ethanolamine, classified under the direct parent group Phosphoethanolamines. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Organic phosphoric acids and derivatives class, specifically within the Phosphate esters subclass.
Categories:
Creatinolfosfate is categorized under the following therapeutic classes: Cardiac Therapy. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Creatinolfosfate is a type of Metabolic Bone Disease Agents
Metabolic Bone Disease Agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically designed to treat and manage conditions related to the bones and their metabolism. These agents play a crucial role in the treatment of various metabolic bone diseases, including osteoporosis, Paget's disease, and rickets.
The primary function of Metabolic Bone Disease Agents is to regulate bone remodeling and maintain bone health. They achieve this by targeting specific pathways involved in bone metabolism, such as osteoclast and osteoblast activity, calcium regulation, and vitamin D metabolism.
These APIs are commonly used in the development of medications, including oral tablets, injectables, and topical formulations, for the effective treatment of metabolic bone diseases. They are carefully formulated to optimize their pharmacokinetic and pharmacodynamic properties, ensuring maximum efficacy and minimal side effects.
Metabolic Bone Disease Agents encompass a range of substances, including bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, and vitamin D analogs. These APIs act through different mechanisms to address specific aspects of bone health, such as inhibiting bone resorption, promoting bone formation, or regulating calcium levels.
In conclusion, Metabolic Bone Disease Agents are a vital category of pharmaceutical APIs used in the development of medications for the treatment and management of various metabolic bone diseases. These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions.
